InflaRx N.V.IFRX

InflaRx N.V. has closed a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share, netting the company fresh capital and handing Guggenheim Securities a placement fee for the privilege. The deal doubles the company’s equity base overnight and arrives with no accompanying disclosure on cash flow, operating income, or guidance, leaving investors to guess whether the new cash will outrun the burn before the next financing.

Behind the capital raise sits a pipeline of complement-targeting anti-inflammatories, led by izicopan, an oral C5a receptor inhibitor that the company now intends to advance into ANCA-associated vasculitis and select renal diseases. The announcement follows FDA interactions that the company describes as concluding an “optimized clinical development program,” a phrasing that typically precedes a formal protocol submission rather than a regulatory rubber stamp.

The company’s lead asset, vilobelimab, is heading toward a late-breaker oral presentation of Phase 3 results in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting, a skin disease so rare that its incidence is measured in cases per million rather than patients per trial site. In the absence of published Phase 3 data, the meeting abstract will be the first public glimpse of efficacy and safety in a near-zero-prevalence indication.

InflaRx’s investor relations site lists clinical trials as “sponsored studies” without recruitment status, endpoints, or timelines, and the product page features a placeholder antibody cartoon rather than a molecule structure or formulation details. The company’s most recent financial disclosure remains the March 2023 annual report, which did not include revenues, net income, or operating cash flow, so the only concrete numbers are the 75 million shares sold and the $2 offering price.

The clinical development rail at InflaRx lists a Phase II trial in hidradenitis suppurativa for izicopan, but the page carries no recruitment status, estimated completion date, or primary endpoint, and the company’s own release notes only that “a viable path forward exists” after FDA interactions. Until the company publishes protocol synopses, recruitment dashboards, or even a simple cash runway estimate, the platform story outpaces the filings by an order of magnitude.

The company’s identity page explains that “we are a team of internationally recognized researchers and clinicians who have dedicated our careers to translating discoveries into new therapeutic concepts,” a line that reads less like disclosure and more like a personal statement waiting for data. The balance sheet remains the missing slide in the deck, and until it appears, the market is trading a story, not an operating business.